Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We've exceeded our expectations and theirs, I think, for the first quarter of the collaboration |
| Lastly, WorkSimpli continues to deliver strong financial results, finishing 2023 with 50% year-over-year growth and adjusted EBITDA margins exceeding 25% |
| Our focus on building an incredible healthcare experience for our patients is paying dividends |
| As we prepare to finish the first quarter of 2024, I remain confident in our ability to deliver on our expectations and beyond this year to our patients who trust us with their health, our employees and providers who believe in and advance our mission and our shareholders who continue to support us |
| Today, we are stronger than ever before |
| IQVIA is a great company, and we really like the team there, and we're optimistic that some - that, that will be a fruitful relationship down the road |
| But in general, we've consistently even if we've scaled to the highest volumes per day that we've seen have seen really strong economics |
| I believe this transaction truly validates the strength of our highly differentiated direct-to-patient telehealth platform and offering |
| And we're certainly super excited, about the rest of the year |
| Beyond the consistently strong growth we've seen with RexMD, the brand continues to be immensely profitable, finishing 2023 with a contribution margin in excess of 30% |
| In addition, our noncore subsidiary WorkSimpli continued its consistent growth trajectory with 50% year-over-year revenue growth and EBITDA margins exceeding 25% |
| I am pleased to report that 2024 is off to a strong start and that we remain well positioned for sustained growth and profitability |
| But I can tell you we're very happy |
| As we've shared in our remarks, retention rates so far have been very, very strong |
| They are now earning more per user, and their economics and their margins have gotten substantially better while still being able to grow the top line of their business |
| Our tremendous growth, which continues to accelerate in pace is largely attributable to our highly differentiated service-based offering leveraging our primary care platform to provide our weight management patients comprehensive end-to-end care for their weight loss goals |
| Early retention results continue to be impressive with over 80% of patients who start therapy remaining on therapy after 90 days |
| Economics for these patient groups remain very strong with day one net revenue over ad spend exceeding 1x |
| They're increasing the company's profitability |
| So it's been a very, very strong month |
| And congrats with another record quarter |
| Our Lifestyle Healthcare business, led by RexMD, had its fourth consecutive year of double-digit annual revenue growth |
| We expect continued double-digit growth in this market while also introducing complementary new products designed not only to capture share in adjacent markets, but to provide substantial cross-sell opportunities for our existing REX patients |
| Over 160,000 and growing REX patients tend to be well established in their lives with ample disposable income, and they appreciate the quality of care they receive from LifeMD affiliated providers |
| So, I think this is - look, the business is doing great, as you can tell by our remarks, and the numbers we put out and, but this is something that like we have, we're putting a lot of resources into internally |
| With that said, 2023 was a tremendous and record-setting year for LifeMD |
| Telehealth net revenues grew 19% versus the prior year, while WorkSimpli revenues grew 50% |
| And as we said - in our remarks, we're seeing excellent growth and we're extremely bullish on this business overall |
| We believe that allowing our patients to use their insurance to offset the cost of our virtual and in-home care services will accelerate demand for our service offering and drive better retention |
| Also super bullish, for what it's doing for our platform |
| Statement |
|---|
| And so, I just - I think they're very difficult business models to sync - to sync with each other |
| While we are slightly delayed from our initial timeline, largely due to resources being focused on meeting the outsized demand we've had in our weight management business |
| I think for a number of reasons, it's been - the adoption rates have been very slow |
| Our GAAP net loss attributable to common stockholders for the fourth quarter totaled $4.5 million or a loss of $0.12 per share |
| The investments we are making in product and operational expansion will only serve to elevate our market share and enhance the experience we deliver |
| This compares with an adjusted EBITDA loss of $14 million in 2022 |
| Our GAAP net loss attributable to common stockholders for full year 2023 totaled $23.7 million or a loss of $0.70 per share |
| Can we get an update on customer acquisition costs, companies like Teladoc and other entities in the mental health space, have talked about increased pricing pressure there |
| There are a lot of compliance issues |
| This compares to a GAAP net loss attributable to common stockholders of $12.7 million or a loss of $0.40 per share in the fourth quarter of 2022 |
| Yes, we do expect user growth to recover |
| And the weight management business, we're actually - as we've scaled to more volume, and I'm not saying this is going to always hold this way, but - we actually have seen CAC slightly decline |
| Reflecting the same adjustments, as I mentioned in the fourth quarter results, adjusted EPS for 2023 was $0.35 per share compared with a loss of $0.45 per share in 2022 |
| Even though a lot of patients right now, the majority of patients, are not getting approved for a brand of therapy, and they're having to resort to a high quality compounded therapy because of that |
| So that brand has matured a little bit |
| This compares to a GAAP net loss attributable to common stockholders of $48.6 million or a loss of $1.57 per share in 2022 |
| That's showing no signs of slowing down |
| It's very difficult to say our goal, is to help patients hit their goal weight, with one of these therapies in a comprehensive way |
| Similar to what we did in 2022, when we refined our base in the Telehealth business to lop off a lot of those trial offers that, were not as profitable |
| But as far as predicting, I think as far as predicting that right now, it's impossible |
Please consider a small donation if you think this website provides you with relevant information